Clinical-stage biopharmaceutical company CureVac AG announced Wednesday that it has received regulatory approval from German and Belgian authorities to initiate Phase 1 clinical trial of its SARS-CoV-2 (COVID-19) vaccine candidate. The trial will start promptly and will be conducted in Germany and Belgium.
from RTT - Biotech https://ift.tt/2Yb5NYV
via IFTTT
No comments:
Post a Comment